San Diego, United States
MBrace Therapeutics is a biopharmaceutical startup founded in 2019, with the mission of improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. Their slogan "We are developing first in class ADC's directed to novel targets to improve the lives of patients with cancer." reflects their focused approach. The company has garnered significant support from a world-class investor syndicate, including TPG Capital, Venrock, Alta Partners, Cowen Digital, and Avidity Partners.
The latest milestone for MBrace Therapeutics is the $85.00M Series B investment that they secured on 14 November 2023. This substantial investment not only validates the potential of the company and its technologies, but it also provides the necessary resources to advance their product pipeline and bring novel treatments to the patients who need them. The fact that this significant investment comes from reputable firms further adds to MBrace's credibility and potential for success in the biotechnology arena.
As a privately-held company headquartered in the United States, MBrace Therapeutics is well-positioned to leverage its investors' expertise and financial backing to make meaningful strides in the field of oncology. With a focus on delivering innovative solutions for cancer treatment, MBrace has the potential to not only make a positive impact on patients' lives but also to yield substantial returns for its investors in the long run.
